MS

Michael Skynner

Chief Technology Officer

Bicycle Therapeutics

Cambridge, England


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
Bicycle Therapeutics
Industry
research
Employees
340.0
Seniority
C suite
Annual Revenue
35275000.0

Technologies

NetSuite Route 53 Mimecast Outlook Microsoft Office 365 Google Cloud Hosting Salesforce WP Engine Mobile Friendly reCAPTCHA WordPress.org Akamai RUM Google Analytics Google Maps (Non Paid Users) Google Font API Nginx New Relic Google Maps Google Tag Manager Remote

Keywords

drug discovery phage display peptide therapeutics biotechnology biotechnology: pharmaceutical preparations health care biotechnology research precision-guided therapeutics solid tumors drug delivery immuno-oncology bicycle molecules targeted therapy peptide design oncology treatments therapeutic applications collaborative partnerships high affinity pharmacological properties biological mimicry bi-cyclic structure tumor-targeted immune cell agonists cd137 agonism epha2 targeting nectin-4 targeting bicycle toxin conjugates bicycle radionuclide conjugates clinical trials preclinical models modular design combination therapy pharmaceutical collaborations anti-infective therapies neuromuscular disorders cardiovascular applications cns therapies disease modulation unmet medical needs new chemical entities pharmacokinetics therapeutic modalities toxicological burden high-value targets synthetic advantages immunogenic memory tumor microenvironment target-selective therapies molecular therapeutics biologics alternatives cell-nanoparticle interactions phage platform antibody-drug conjugates clinical efficacy patient-derived xenografts clinical-stage biopharmaceutical oncology cancer therapeutics btcs bicycle tumor-targeted immune cell agonists bicycle ticas radiopharmaceuticals high unmet medical needs innovative drug development synthetic peptides targeted therapies drug conjugates anti-infective cardiovascular ophthalmology dementia central nervous system neuromuscular respiratory diseases drug development pharmaceutical partnerships patient outcomes transformative medicines novel therapeutic modalities business-to-business healthcare sector cancer indications therapeutic payloads imaging capabilities strategic partnerships emerging pipeline patient demographics investor relations health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans